Holen Sie sich die Stockscreener-App
72.82
10.07%
6.66
Handel nachbörslich:
72.98
0.16
+0.22%
Schlusskurs vom Vortag:
$66.16
Offen:
$67.26
24-Stunden-Volumen:
4.26M
Relative Volume:
1.49
Marktkapitalisierung:
$6.62B
Einnahmen:
$170.10M
Nettoeinkommen (Verlust:
$-239.59M
KGV:
-26.01
EPS:
-2.8
Netto-Cashflow:
$-191.20M
1W Leistung:
+20.72%
1M Leistung:
+38.28%
6M Leistung:
+112.99%
1J Leistung:
+59.31%
1-Tages-Spanne:
$66.57
$72.95
1-Wochen-Bereich:
$58.49
$72.95
52-Wochen-Spanne:
$30.04
$72.95
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Firmenname
Crispr Therapeutics Ag
Sektor
Branche
Telefon
(617) 315-4600
Adresse
BAARERSTRASSE 14, ZUG
Vergleichen Sie CRSP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
72.82 | 6.02B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.85 | 103.64B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.00 | 63.59B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.99 | 60.38B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
791.59 | 46.96B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
345.17 | 36.81B | 4.56B | -176.77M | 225.30M | -1.7177 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | JP Morgan | Overweight |
| 2025-02-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Hochstufung | TD Cowen | Sell → Hold |
| 2025-02-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-08-02 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | Guggenheim | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-11 | Herabstufung | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Eingeleitet | Mizuho | Buy |
| 2023-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-04-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-08-09 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-04-21 | Hochstufung | Jefferies | Hold → Buy |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2020-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-10 | Bestätigt | Needham | Buy |
| 2020-12-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-07-28 | Bestätigt | Needham | Buy |
| 2020-07-14 | Eingeleitet | SunTrust | Buy |
| 2020-06-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Eingeleitet | Jefferies | Buy |
| 2019-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-10 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-14 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-28 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-22 | Herabstufung | Citigroup | Neutral → Sell |
Alle ansehen
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
CRISPR Therapeutics (NASDAQ:CRSP) Trading 8.2% HigherWhat's Next? - MarketBeat
Crispr Therapeutics stock hits 52-week high at 71.14 USD By Investing.com - Investing.com Australia
From 160 Licenses to $1B Raised: Australia's Largest University Opens Boston Hub to Accelerate Biotech Innovation - Stock Titan
BMO Reaffirms Outperform on CRISPR Therapeutics (CRSP) After Sirius Collaboration - MSN
Combining price and volume data for CRISPR Therapeutics AG2025 Top Gainers & Reliable Price Breakout Alerts - newser.com
CRISPR Therapeutics AG stock outlook for YEARJuly 2025 Levels & Weekly High Conviction Ideas - newser.com
Crispr Therapeutics to present preclinical data on AATD at ESGCT 2025 - TipRanks
Signal strength of CRISPR Therapeutics AG stock in tech scanners2025 Volatility Report & Real-Time Buy Zone Alerts - newser.com
CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress - The Manila Times
CRISPR Therapeutics to Present Novel SyNTase Gene Editing Technology at ESGCT 2025 Annual Congress - Quiver Quantitative
Leading vs lagging indicators on CRISPR Therapeutics AG performance2025 EndofYear Setup & Growth Focused Stock Reports - newser.com
CRISPR Therapeutics to Present Preclinical Data on Alpha-1 - GlobeNewswire
What valuation ratios show for CRISPR Therapeutics AG (1CG) stockEarnings Miss & High Return Trade Opportunity Guides - newser.com
CRISPR's SyNTase Gene Editor Shows 95% Efficacy in AATD Models | CRSP Stock News - Stock Titan
Got $200? 2 Healthcare Stocks to Buy and Hold Forever - The Motley Fool
H.C. Wainwright Reiterates Buy Rating on CRISPR Therapeutics AG (CRSP) Stock - Yahoo Finance
U.S. Gene Editing Market Projections 2025-2032: Key Trends, - openPR.com
CRISPR Therapeutics AG (CRSP): the Most Oversold Pharma Stock to Buy According to Analysts - MSN
H.C. Wainwright Reaffirms Buy Rating on CRISPR Therapeutics After CTX310 Update - msn.com
Could This Beaten-Down Stock Help You Become a Millionaire? - AOL.com
Relative strength of CRISPR Therapeutics AG in sector analysisTrade Risk Summary & Fast Moving Stock Watchlists - newser.com
What analysts say about CRISPR Therapeutics AG stockVWAP Trading Strategies & Exceptional Return Opportunities - earlytimes.in
Does CRISPR Therapeutics AG qualify in momentum factor screeningPortfolio Profit Report & Stock Market Timing Techniques - newser.com
Order flow analysis tools used on CRISPR Therapeutics AG2025 Retail Activity & Fast Gain Swing Trade Alerts - newser.com
Published on: 2025-09-29 09:36:12 - newser.com
Published on: 2025-09-29 07:23:14 - newser.com
Measuring CRISPR Therapeutics AG’s beta against major indices2025 Major Catalysts & High Yield Equity Trading Tips - newser.com
Will a bounce in CRISPR Therapeutics AG offer an exit2025 Market Overview & Risk Managed Investment Entry Signals - newser.com
What candlestick patterns are forming on CRISPR Therapeutics AGJuly 2025 Catalysts & Detailed Earnings Play Strategies - newser.com
Published on: 2025-09-29 03:07:00 - newser.com
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Published on: 2025-09-29 01:02:34 - newser.com
What drives CRISPR Therapeutics AG stock priceDividend Reinvestment Plans & Big Data Market Reports - earlytimes.in
Is CRISPR Therapeutics AG a good long term investmentSupport and Resistance Levels & Access Free Risk Analysis Before You Invest - earlytimes.in
Published on: 2025-09-27 21:01:29 - newser.com
Is the First Phase 2 Dosing of SRSD107 Shifting CRISPR Therapeutics’ (CRSP) Investment Landscape? - Sahm
Voya Investment Management LLC Boosts Stock Position in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why - sharewise.com
CRISPR Therapeutics AG Stock Analysis and ForecastOptions Trading Strategies & Low Risk Investment Trading - Early Times
Wealth Enhancement Advisory Services LLC Decreases Stock Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
Exchange Traded Concepts LLC Acquires New Shares in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know - sharewise.com
Bouvel Investment Partners LLC Acquires 9,458 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
BMO Capital reiterates Outperform on CRISPR Therapeutics stock, sees potential in thrombosis market - Investing.com Nigeria
Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now? - sharewise.com
CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU - Yahoo Finance
Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):